John's mailing address filed with the SEC is C/O CELLECTAR BIOSCIENCES, INC., 3301 AGRICULTURE DRIVE, MADISON, WI, 53716.
Over the last 10 years, insiders at Cellectar Biosciences Inc have traded over 1,263,511$ worth of Cellectar Biosciences Inc stock and bought 1,917,793 units worth 3,966,598$ . The most active insiders traders include Austin W & Greenhouse David...、Investment Company, Inc. Awm、John Neis. On average, Cellectar Biosciences Inc executives and independent directors trade stock every 50 days with the average trade being worth of 126,821$. The most recent stock trade was executed by Douglas J Swirsky on 14 September 2021, trading 25,000 units of CLRB stock currently worth 26,000$.
cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p
Cellectar Biosciences Inc executives and other stock owners filed with the SEC include: